All In MedTech

Device Trial Radar · NCT07541404

MMA Embolization With NeoCast for Subacute and Chronic Subdural Hematoma

Pivotal Study of the Treatment of Symptomatic Subacute and Chronic Subdural Hematoma Via Middle Meningeal Artery Embolization With the NeoCastTM Embolic System (RADIANT)

Last checked: Nov 20, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingTitle says "pivotal". Randomized with 360 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

360

Planned (sponsor's estimate)

Start

Aug 13, 2026

Primary completion

Jan 2028

Study completion Apr 2028

Sponsor

Lead sponsor
Arsenal Medical, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Apr 21, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of embolization of the middle meningeal artery (MMA) using the NeoCast Embolic System for treatment of symptomatic subacute or chronic subdural hematoma (SDH) adjunctive to surgery.

Conditions

  • Subdural Hematoma

Interventions

  • NeoCast Embolic SystemDevice

    NeoCast will be used to embolize a participant's middle meningeal artery in an endovascular procedure before or after adjunctive surgery to drain the hematoma

  • Onyx LES, an FDA-Approved Commercial Liquid EmbolicDevice

    Onyx LES, an FDA-approved commercial liquid embolic, will be used to embolize a participant's middle meningeal artery in an endovascular procedure before or after adjunctive surgery to drain the hematoma

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Comparison of NeoCast arm vs. Onyx LES arm for a composite endpoint of treatment failure eventsTime frame: 90 Days post-treatment
  2. Safety Outcomes including Device-related or Procedure-related Serious Adverse EventsTime frame: 180 days post-treatment

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Yale Neurosciences Institute

    New Haven, Connecticut · Not yet recruiting

  • University of Washington Medicine - Harborview Medical Center

    Seattle, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.